Eli Lilly and Company (LLY) Stock Forecast & Price Target

$877.50

-31.82 (-3.50%)

(As of 09/27/2024 ET)

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
3

Buy
16

Based on 19 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 3 have given a hold rating, and 16 have given a buy rating for LLY.

Consensus Price Target

$977.35
11.38% Upside

According to the 19 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $977.35. The highest price target for LLY is $1,125.00, while the lowest price target for LLY is $710.00. The average price target represents a forecasted upside of 11.38% from the current price of $877.50.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

LLY Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	19 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$977.35	$961.76	$812.72	$532.78
Forecasted Upside	11.38% Upside	2.22% Upside	-10.23% Downside	-0.78% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The election trade you can't lose (Ad)

Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.

Download my Dividend Calendar here

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	11.38% Upside	818.47% Upside	6.12% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$885.00 ➝ $885.00	-4.27%
9/13/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$1,050.00 ➝ $1,100.00	+17.67%
9/13/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$1,060.00	+13.36%
9/5/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/27/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$1,106.00 ➝ $1,106.00	+16.36%
8/16/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$884.00 ➝ $1,030.00	+10.89%
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
8/14/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,000.00 ➝ $1,050.00	+13.30%
8/12/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$725.00 ➝ $1,025.00	+14.95%
8/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$875.00 ➝ $1,000.00	+11.94%
8/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,000.00 ➝ $1,125.00	+33.20%
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$1,001.00 ➝ $1,101.00	+30.36%
7/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$913.00 ➝ $1,025.00	+9.04%
6/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$892.00 ➝ $1,000.00	+12.28%
6/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$994.00 ➝ $1,015.00	+12.98%
5/14/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$770.00 ➝ $840.00	+11.04%
4/11/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$650.00 ➝ $723.00	-5.02%
4/3/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/21/2024	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$820.00	+8.50%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$612.00 ➝ $710.00	+20.28%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
8/8/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$560.00	+28.82%
6/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/1/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$410.00 ➝ $458.00	+15.70%
4/28/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
2/15/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell	$278.00	-18.41%
12/16/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$384.00 ➝ $410.00	+13.93%
12/5/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$390.00 ➝ $430.00	+14.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:13 AM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 10, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

Eli Lilly and Co reported an impressive quarterly earnings data, surpassing the consensus estimate by a significant margin, indicating strong financial performance.
The company has a high return on equity of 67.52%, showcasing efficient utilization of shareholder funds to generate profits.
Insider transactions show major shareholders selling shares at a high price, suggesting confidence in the company's future growth prospects.
Eli Lilly and Co has a stable dividend payout ratio of 76.58%, providing investors with a consistent income stream.
Institutional investors have been increasing their stakes in the company, indicating confidence in its long-term potential.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

The company's debt-to-equity ratio of 1.74 is relatively high, indicating a higher level of financial leverage which may pose risks during economic downturns.

LLY Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $977.35, with a high forecast of $1,125.00 and a low forecast of $710.00.
: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LLY shares.
: According to analysts, Eli Lilly and Company's stock has a predicted upside of 11.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Eli Lilly and Company's stock had 2 upgrades by analysts.
: Eli Lilly and Company has been rated by research analysts at Bank of America, Barclays, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, and Wells Fargo & Company in the past 90 days.
: Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.84 while the average consensus rating score for "medical" companies is 2.78. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The election trade you can't lose (Ad)

Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.

Download my Dividend Calendar here

This page (NYSE:LLY) was last updated on 9/28/2024 by MarketBeat.com Staff

From Our Partners